a7bda5b9-9c95-4f90-bab6-10ab15ee2b48
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- TGF_BETA_SIGNALING+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- HEDGEHOG_SIGNALING+0.300
- PROTEIN_SECRETION+0.300
- HYPOXIA+0.200
- MITOTIC_SPINDLE+0.200
- UV_RESPONSE_DN+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- ANDROGEN_RESPONSE+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- E2F_TARGETS-0.300
- FATTY_ACID_METABOLISM-0.300
- MYC_TARGETS_V2-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- XENOBIOTIC_METABOLISM-0.300
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208936 | — | — | 0.814 |
| 2 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.789 |
| 3 | SRR8613779 | — | D | 0.784 |
| 4 | c2bfde36-4ebd-48d7-8662-cf82253a3eab | — | — | 0.775 |
| 5 | TCGA-BH-A0EI-01A-11R-A115-07 | — | B | 0.770 |
| 6 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.768 |
| 7 | SRR8518326 | — | E | 0.764 |
| 8 | 20120162.TNBC | — | E | 0.759 |
| 9 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.758 |
| 10 | 50d521bc-fb39-4811-9126-09f092623809 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |